HVEM-LIGHT signaling promotes antibody-dependent neutrophil FcγR-mediated trogocytosis against herpes simplex virus infection
Journal of Clinical Investigation · 15.07.2026 · 136 (14)
DOI: 10.1172/jci203771 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 04.06.2026. Verfasst von Matthew S Gromisch und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Receptors, IgG, Receptors, Tumor Necrosis Factor, Member 14, Neutrophils, Signal Transduction. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Studies with a candidate vaccine deleted in glycoprotein D (ΔgD-2) for herpes simplex virus (HSV) prevention uncovered a role for herpes virus entry mediator (HVEM) in mediating antibody-dependent cell-mediated killing (ADCK) of virally infected cells. Antibodies elicited by ΔgD-2 passively protect WT but not Fc γ receptor (FcγR) or HVEM knockout (KO) mice. The goals of this study were to identify which cells mediate ADCK and the role of HVEM signaling. Using HVEM ligand and conditional cell-type–specific HVEM-KO mice combined with in vitro mouse and human cytolytic assays, we demonstrate that ADCK of HSV-infected cells is mediated primarily by neutrophils and requires their expression of HVEM and its ligand, LIGHT. Cytolysis is not associated with granzyme and perforin production but occurs by a trogocytosis-like pathway. Pharmacological inhibition of myosin light-chain kinase (MLCK), which mediates trogocytosis, inhibits cytolysis. Similar results were obtained when human neutrophils were cocultured with HSV-infected cells opsonized with ADCK-containing human immune serum or with breast cancer cells treated with an anti-HER2 trogocytosis mediating antibody. Killing was significantly reduced when an MLCK inhibitor or blocking antibodies to CD16a, HVEM, or LIGHT were added. Together, these results define a mechanism of HVEM-enhanced FcγR-mediated neutrophil-dependent ADCK of targets cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, New York, USA.
- Department of Immunology, Duke University School of Medicine, Durham, North Carolina, USA.
- Infectious and Inflammatory Diseases Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
- Department of Biochemistry and.
- Department of Pediatrics, Albert Einstein College of Medicine, New York, New York, USA.
Förderung
- NIAID NIH HHS
- NIH HHS
- NCI NIH HHS
- US National Institutes of Health
- NIAID
- Rowland and Sylvia Schaefer Family Foundation, Inc.
Zitieren
APA
Gromisch, M. S., Kuraoka, M., Ware, C. F., Almo, S. C., & Herold, B. C. (2026). HVEM-LIGHT signaling promotes antibody-dependent neutrophil FcγR-mediated trogocytosis against herpes simplex virus infection. Journal of Clinical Investigation, 136(14). https://doi.org/10.1172/jci203771
Vancouver
Gromisch MS, Kuraoka M, Ware CF, Almo SC, Herold BC. HVEM-LIGHT signaling promotes antibody-dependent neutrophil FcγR-mediated trogocytosis against herpes simplex virus infection. Journal of Clinical Investigation. 2026;136(14). doi:10.1172/jci203771
BibTeX
@article{Gromisch2026,
author = {Gromisch, Matthew S and Kuraoka, Masayuki and Ware, Carl F and Almo, Steven C and Herold, Betsy C},
title = {HVEM-LIGHT signaling promotes antibody-dependent neutrophil FcγR-mediated trogocytosis against herpes simplex virus infection},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {14},
doi = {10.1172/jci203771}
}
EUVIMED